Why we invested

Heart failure presents a significant challenge in management due to limitations in current monitoring methods—such as blood biomarkers, echocardiography, and physical assessments—which often fail to deliver accurate and comprehensive insights into a patient’s condition. These standard approaches can lead to high rates of hospital readmissions, high healthcare costs, and less effective treatment, as they may miss critical changes in intracardiac pressure, a key measure for HF patients. While intracardiac pressure monitoring (ICPM) has been shown to reduce HF hospitalizations, existing ICPM options are invasive, making them unsuitable for widespread use in many clinical settings.

Acorai’s solution is a non-invasive, handheld device that provides an accurate measurement of pulmonary artery pressure, comparable to invasive ICPM devices, without the need for surgical implantation. The device offers a practical and accessible way for clinicians to obtain critical hemodynamic data, which enhances in-hospital decision-making, allows for faster optimization of guideline-directed medical therapy, and improves clinician productivity. By making reliable HF monitoring more accessible, Acorai’s device has the potential to improve patient outcomes, reduce readmissions, and significantly lower the cost of HF management.

Founding team